After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Acadia Pharmaceuticals Inc is $2.78B. A total of 1.82 million shares were traded on the day, compared to an average of 1.34M shares.
In the most recent transaction, Teehan Brendan sold 10,329 shares of ACAD for 16.81 per share on Nov 19 ’24. After the transaction, the EVP, COO, HEAD OF COMMERCIAL now owns 62,105 company shares. In a previous transaction on Nov 19 ’24, Kihara James sold 4,073 shares at 16.81 per share. ACAD shares that PRINCIPAL ACCOUNTING OFFICER owns now total 19,863.
Among the insiders who sold shares, Schneyer Mark C. disposed of 10,259 shares on Nov 19 ’24 at a per-share price of $16.81. This resulted in the EVP, CHIEF FINANCIAL OFFICER holding 53,302 shares of ACAD after the transaction. In another insider transaction, Schneyer Mark C. sold 9,733 shares at $15.28 per share on Aug 19 ’24. Company shares held by the EVP, CHIEF FINANCIAL OFFICER now total 43,735.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, ACAD has a high of $32.59 and a low of $14.15.
As of this writing, ACAD has an earnings estimate of $0.23 per share for the current quarter. EPS was calculated based on a consensus of 15.0 estimates, with a high estimate of $0.64 per share and a lower estimate of $-0.07. The company reported an EPS of $0.28 in the last quarter
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $3.47, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.14.
